San Diego – July 9, 2018 – Cooley advised Helix on the closing of its $200 million Series B financing round led by DFJ Growth. Cooley lawyer Josh Seidenfeld led the team, supported by partners Wainwright Fishburn and Glen Sato.
In addition to DFJ, the round included participation from Temasek and existing investors Illumina, Kleiner Perkins Caufield Byers, Mayo Clinic, Sutter Hill Ventures and Warburg Pincus. As part of the transaction, DFJ partner and former America Online CEO Barry Schuler will join Helix’s board of directors. The company reports that the funding will accelerate consumer adoption of genomics through the expansion of its trusted marketplace.
“Helix is entering an exciting phase of tremendous growth and opportunity. Our marketplace is maturing, we are expanding our health-related product offerings and we’re building a community of loyal and engaged customers,” said Robin Thurston, CEO of Helix, in a news release.
Helix is a personal genomics company with a simple but powerful mission: to empower every person to improve their life through DNA. It has created the first marketplace for DNA-powered products where people can explore diverse and uniquely personalized products developed by high-quality partners.
“We are clearly entering the next phase in personal genomics,” said Fishburn, who also chairs the Digital Health Track at the BIO International Convention. “We are honored to advise companies like Helix at the forefront of shaping the new healthcare economy.”
Cooley has 250+ clients in the digital health client space. In 2015, Cooley advised on the formation of Helix.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.